Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-COG-CROOP-ADVL1217
Principal InvestigatorCroop, James
PhasePhase I
Age GroupChildren
TitleADVL1217, A Phase 1 Study of MK-1775(IND# 116495) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas
DescriptionThis phase I trial studies the side effects and the best dose of MK-1775 (WEE1 inhibitor MK-1775) when given together with local radiation therapy in treating patients with newly diagnosed diffuse intrinsic pontine gliomas. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving WEE1 inhibitor MK-1775 with local radiation therapy may be an effective treatment for diffuse intrinsic pontine gliomas.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Age 37 months to 21 years
  • Newly diagnosed DIPGs (patients with disseminated disease are not eligible)
  • Patients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG
For a full list of participation criteria, please visit
Applicable Disease SitesBrain Tumors (Child)
Nervous System Tumors
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: +1 317-944-4281
Pager: 312-1228